Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

11. August 2026 aktualisiert von: BrainJuice

This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.

Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Be male or female
  • Be aged 18-57
  • Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease
  • If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
  • Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
  • Willing to maintain the same diet and exercise regimen consistently throughout the study duration
  • Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
  • Resides in the United States
  • Has access to a computer or tablet device

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
  • History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
  • History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
  • History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
  • Anyone with a job that involves shift work that may be overnight or night hours
  • Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
  • Anyone with any allergies or sensitivities to any of the study product ingredients
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Anyone unwilling to follow the study protocol
  • Anyone with a history of substance abuse
  • Anyone who is currently a smoker or has been a smoker in the past 3 months
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: BrainJuice Supplement
Nahrungsergänzungsmittel: BrainJuice Supplement
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Cognitive Assessment Score (Polygons)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Double Trouble)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Feature Match)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Paired Associates)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Digit Span)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Spatial Planning)
Zeitfenster: Baseline, Week 2, Week 4, and Week 6
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Self-Reported Focus
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization
Zeitfenster: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

BrainJuice

Mitarbeiter

Citruslabs

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. November 2025

Primärer Abschluss (Tatsächlich)

6. Februar 2026

Studienabschluss (Tatsächlich)

6. Februar 2026

Studienanmeldedaten

Zuerst eingereicht

11. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. August 2026

Zuerst gepostet (Tatsächlich)

14. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 20807 (Andere Kennung: Fred Hutch/University of Washington Cancer Consortium)
  • legacy-20807

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren